The firm reported a 13 percent jump in its non-COVID molecular diagnostics revenues year over year while its breast health and GYN Surgical business revenues rose 6 percent.

The firm's Q3 2024 revenues rose 33 percent year over year as both its genomics and data and services revenues increased in the double-digit percent range.

Fadel Alshalabi, owner and CEO of Crestar Labs, and Samuel Harris, owner of Flojo Recruiting conspired to bill Medicare and Medicaid for millions of dollars in genetic test orders.

Last week, readers were most interested in a story about the FDA's clearance of Qiagen's QiaStat-Dx Respiratory Panel Mini syndromic multiplex qPCR test.

Out of the 30 companies tracked by 360Dx, 22 saw their share prices decline, seven saw their stock prices increase, and one company’s shares remained essentially flat.

The firm also appointed Aaron Roebuck as president, saying he will help the company to develop and commercialize its breath-based testing platform.

The parliamentary resolution drew the immediate support of MedTech Europe and VDGH, but it remains unclear what the immediate ...

The upgrade is based on the firm's improving growth, more reasonable valuations, and its ability to deploy capital.

The firm said that demand has increased for its 10-minute sepsis risk test as it can save lives, reduce hospital stays, and reduce healthcare costs.